The prognosis of patients with EGFR-mutant NSCLC has dramatically improved since EGFR tyrosine kinase inhibitors (TKIs) were introduced in the clinical setting as first-line therapy, and even more so with the potent third-generation drug Osimertinib [4]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.